Back
Top 1.0%
17.6%
#1
14.5%
Top 4%
6.4%
Top 72%
6.4%
Top 2%
6.4%
Top 16%
6.4%
Top 3%
5.5%
Top 0.8%
5.0%
Top 2%
3.0%
Top 6%
1.9%
Top 3%
1.9%
Top 2%
1.5%
Top 86%
1.5%
Top 17%
1.3%
Top 7%
1.3%
Top 7%
1.3%
Top 7%
1.1%
Top 2%
0.9%
Top 63%
0.9%
Top 7%
0.7%
Top 7%
0.7%
The CSF-1R inhibitor Pexidartinib impacts dendritic cell differentiation through inhibition of FLT3 signaling and may antagonize the effect of durvalumab in patients with advanced cancer - results from a phase 1 study
2023-02-23
oncology
Title + abstract only
View on medRxiv
Show abstract
Tumor-associated macrophages (TAM) are critical determinant of resistance to programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) blockade. This phase I study (MEDIPLEX, NCT02777710) investigated the safety and efficacy of pexidartinib, a CSF-1R-directed tyrosine kinase inhibitor (TKI), and durvalumab (anti-PD-L1) in patients with advanced colorectal (CRC) and pancreatic (PDAC) carcinoma with the aim to enhance responses to PD-L1 blockade by eliminating CSF-1-dependent suppressive TAM. No u...
Predicted journal destinations
1
Cancers
57 training papers
2
Clinical Cancer Research
22 training papers
3
eLife
262 training papers
4
PLOS ONE
1737 training papers
5
Frontiers in Oncology
34 training papers
6
Nature Communications
483 training papers
7
Frontiers in Immunology
140 training papers
8
British Journal of Cancer
22 training papers
9
Cancer Medicine
17 training papers
10
Proceedings of the National Academy of Sciences
100 training papers
11
BMC Cancer
21 training papers
12
Journal of Clinical Investigation
50 training papers
13
Scientific Reports
701 training papers
14
JAMA Network Open
125 training papers
15
Nature Medicine
88 training papers
16
iScience
74 training papers
17
Heliyon
57 training papers
18
Cell Reports
25 training papers
19
BMJ Open
553 training papers
20
International Journal of Molecular Sciences
39 training papers
21
Cell Reports Medicine
49 training papers